Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

News

Pfizer reignites Prevenar war

Posted 20 January 2021 PM

There's no let-up in the legal battle over the blockbuster pneumococcal vaccine Prevenar 13, with Pfizer going back to court to appeal two aspects of a judgment it won significantly against rival MSD in October last year.

Although Pfizer successfully stopped MSD from supplying its 15-valent vaccine in Australia for the course of the patent, at the time, it said it would appeal aspects of the decision.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
How not to reform the PBAC
In the face of deep change, is piecemeal enough?
Approvals Action
New registrations for seizures and HIV
Eisai and ViiV add to their core franchises
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas